Diroximel Fumarate for Multiple Sclerosis: Innovative Capsule
About
We (IQGEN-X company and college) aimed to formulate a single 462 mg DRF capsule, in a delayed-release format, as an alternative to the current regimen of Vumerity®, a marketed product administered as two capsules of 231 mg each capsule. In vitro dissolution studies assessed drug release patterns.
Partnering listings
Learn more
Sign up to view the full profile.
Explore areas of focus, current work, and collaboration capabilities.